Drug Profile
Multiple sclerosis vaccine - Pharmasynthez
Alternative Names: XemysLatest Information Update: 01 Oct 2019
Price :
$50
*
At a glance
- Originator Pharmasyntez
- Class Oligopeptides; Peptide vaccines; Vaccines
- Mechanism of Action CD antigen modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 01 Oct 2019 Discontinued - Phase-II for Multiple sclerosis (Recurrent, Treatment-experienced) in Russia (SC)
- 01 Apr 2016 Phase-II clinical trials in Multiple sclerosis (Recurrent, Treatment-experienced) in Russia (SC) (before April 2016)
- 01 Apr 2016 Safety and efficacy data from a phase IIa trial in Multiple sclerosis (Recurrent, Treatment-experienced) released by Pharmasynthez